Quantcast

Latest Genentech Stories

2014-08-24 12:20:28

-- Roche to acquire InterMune for $74.00 per share -- BASEL, Switzerland, Aug. 24, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc. (NASDAQ: ITMN) today announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of $74.00 per share in an all-cash transaction. This corresponds to a total transaction value of $8.3 billion on a fully diluted basis. This offer represents a premium of 38% to InterMune's...

2014-08-20 23:05:37

Top Healthcare Talent, Companies and Brand Champions to be Honored September 18th New York, NY (PRWEB) August 20, 2014 The finalists are in for the sixth-annual PM360 Trailblazer Awards. PM360, a leading health-marketing industry trade magazine, will honor the pharmaceutical industry’s most influential innovators. Established in 2009, the Trailblazer Awards are given to outstanding companies, marketers and brand managers representing the best the industry has to offer. “We are proud...

2014-08-18 16:27:51

SUNNYVALE, Calif., Aug. 18, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has appointed Shawn Cline Tomasello as its Chief Commercial Officer. Ms. Cline Tomasello is a 30-year industry veteran and former President of the Americas, Hematology and Oncology, for the Celgene Corporation, where she managed over $4 billion in revenue. Prior to joining Celgene, Ms. Cline Tomasello was the National Director of Hematology for Rituxan(® )at Genentech, where...

2014-08-14 12:27:38

Over Three-Quarters of Physicians View Ophthotech's Fovista as an Emerging Therapy with High Potential Value for Wet AMD, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 14, 2014 /PRNewswire/ -- Decision Resources Group finds that physician-reported patient shares for Regeneron's Eylea, as well as the other major anti-vascular endothelial growth factor (VEGF) agents Genentech/Roche's Avastin and Genentech/Roche's Lucentis, have now stabilized among wet age-related...

2014-07-30 12:27:14

New PSA Inspires Everyone to Come Together in the Spirit of Collaboration and to Advance Cancer Research LOS ANGELES and NEW YORK, July 30, 2014 /PRNewswire-USNewswire/ -- Stand Up To Cancer (SU2C), a program of the Entertainment Industry Foundation, and Genentech, one of the world's leading biotech companies, have joined forces with GRAMMY(®)-winning singer, Oscar(®)-winning actress, and SU2C Ambassador Jennifer Hudson for their latest campaign, entitled: "Two Worlds. One Dream."...

2014-07-24 23:11:48

Pharmica Consulting, the industry leader in life science processes and technology, is pleased to announce that Naseem Buckley of Genentech will speak at Pharmica’s SharePoint Conference for the Life Sciences Industry on September 30th and October 1st in San Diego, CA. San Diego, CA (PRWEB) July 24, 2014 As part of its continued service to the industry, Pharmica will host its 11th SharePoint conference in San Diego, CA on September 30 and October 1, 2014. The two-day conference will...

2014-07-24 12:27:40

While Expressing Concerns about Reimbursement, EU5 Payers Look Favorably on Identifying Anti-IL5 Therapy-Responsive Patients, According to Findings from Decision Resources Group BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first once-daily long-acting beta2 agonist/inhaled corticosteroid...

2014-07-01 08:29:44

Former Genentech executive to lead Moderna's first venture company, focused exclusively in novel biology for oncology drug development CAMBRIDGE, Mass., July 1, 2014 /PRNewswire/ -- Moderna Therapeutics, the pioneer in developing messenger RNA (mRNA) Therapeutics(TM), a revolutionary treatment modality to enable the in vivo production of therapeutic proteins, announced today that Stephen Kelsey, M.D., will become president of Onkaido Therapeutics, Moderna's oncology drug development...

2014-06-16 08:29:32

The Lung-MAP trial uses a multi-drug, targeted screening approach to match patients with promising new cancer treatments based on their unique tumor profiles BETHESDA, Md., June 16, 2014 /PRNewswire/ -- A unique public-private collaboration among the National Cancer Institute (NCI), part of the National Institutes of Health, SWOG Cancer Research, Friends of Cancer Research (Friends), the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen,...

2014-06-10 16:27:04

INCLINE VILLAGE, Nev., June 10, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the second quarter ending June 30, 2014, of approximately $140 million, as compared with actual revenue of $143.6 million for the second quarter of 2013, an approximate 3 percent decrease. The forecasted revenues are driven by increased first quarter 2014 sales for Avastin(®), Herceptin(®), Xolair(®), Kadcyla(®), Perjeta(®) and Actemra(®) for which PDL...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related